Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Chamone,D.A.F. (2) Dorlhiac-Llacer,P.E. (2) Azevedo,M.C. (1) Buccheri,V. (1) Carneiro,R.C.G. (1) Maranhão,R.C. (1) Marquezini,M.V. (1) Toffoletto,O. (1) Velloso,E.D.R.P. (1) Mais... Palavra-chave Acute myelogenous leukemia (1) Acute myeloid leukemia (1) Chemotherapy (1) Consolidation therapy (1) Cytotoxicity (1) Daunorubicin (1) High-dose cytarabine (1) LDE complex (1) Low-density lipoprotein (1) Prognosis (1) RT-PCR (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2015 (1) 2001 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells BJMBR Dorlhiac-Llacer,P.E.; Marquezini,M.V.; Toffoletto,O.; Carneiro,R.C.G.; Maranhão,R.C.; Chamone,D.A.F.. Acute myelogenous leukemia (AML) blast cells show high-affinity degradation of low-density lipoprotein (LDL), suggesting an increased expression of cellular LDL receptors. LDE is a lipid microemulsion easily synthesized in vitro which is known to mimic the metabolic pathway of LDL. We used LDE as a carrier for daunorubicin and assayed the cytotoxicity of the complex using AML blast cells since RT-PCR analysis showed that AML cells express LDL receptor mRNA. The LDE:daunorubicin complex killed 46.7% of blast cells and 20.2% of normal bone marrow cells (P<0.001; Student t-test). Moreover, this complex destroyed AML blast cells as efficiently as free daunorubicin. Thus, LDE might be a suitable carrier of chemotherapeutic agents targeting these drugs to... Tipo: Info:eu-repo/semantics/article Palavras-chave: Cytotoxicity; Acute myelogenous leukemia; Daunorubicin; Low-density lipoprotein; LDE complex; RT-PCR. Ano: 2001 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001001000004 Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia BJMBR Azevedo,M.C.; Velloso,E.D.R.P.; Buccheri,V.; Chamone,D.A.F.; Dorlhiac-Llacer,P.E.. In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined. We evaluated survival after calculating the actual dose of cytarabine that patients received for consolidation therapy and divided them into 3 groups according to dose. We conducted a single-center, retrospective study involving 311 non-promyelocytic AML patients with a median age of 36 years (16-79 years) who received curative treatment between 1978 and 2007. The 131 patients who received cytarabine consolidation were assigned to study groups by their cytarabine dose protocol. Group 1 (n=69) received <1.5 g/m2 every 12 h on 3... Tipo: Info:eu-repo/semantics/article Palavras-chave: Acute myeloid leukemia; Chemotherapy; Consolidation therapy; High-dose cytarabine; Prognosis. Ano: 2015 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000200178 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco